Active Biotech AB Interim report January - March 2018

12:00 EDT 17 May 2018 | GlobalNewsWire (2014)


First quarter in brief

Events after the end of the period

  • The rights issue implemented in April was oversubscribed by approximately 30 percent. The company received a capital infusion of approximately SEK 46,9 M after issue expenses
  • Our partner NeoTX presented new preclinical data for ANYARA at the AACR Annual Meeting in Chicago

Financial summary

SEK M Jan-Mar Full-year
  2018 2017   2017
Net sales 4.8 4.7   20.2
Operating loss -8.5 -14.6   *-102.5
Loss after tax -10.2 -15.8   *-108,8
Loss per share (SEK) -0.11 -0.16   -1.12
Cash and cash equivalents (at close of the period) 12.8 62.7   25.2

   * of which write down of property SEK 50 M

For further information, please contact:

  Helén Tuvesson, CEO
  Tel: +46 (0)46-19 21 56


  Hans Kolam, CFO
  Tel: +46 (0)46 19 20 44

Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00


The report is also available at

Active Biotech AB Interim report January - March 2018

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire


More From BioPortfolio on "Active Biotech AB Interim report January - March 2018 "

Quick Search


Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...